Optimization of Acute Treatment in First Episode Schizophrenic Patients by New Pharmacological Treatments

Ludwig-Maximilians - University of Munich1 site in 1 country300 target enrollmentNovember 2000

ConditionsSchizophrenia, First-Episode

DrugsRisperidone, Haloperidol

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Schizophrenia, First-Episode
Sponsor: Ludwig-Maximilians - University of Munich
Enrollment: 300
Locations: 1
Primary Endpoint: weekly assessment of psychopathology (e.g.PANSS)and side-effects
Last Updated: 20 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The study is a multicenter, double-blind, randomized, parallel-group study with first episode schizophrenic patients. During a treatment phase of 8 weeks the patients are treated with Risperidone or Haloperidol. Aim of the project is to compare the effects of the atypical neuroleptic Risperidone with those of the conventional neuroleptic Haloperidol and to evaluate whether the assumed advantages of atypical neuroleptics compared to conventional neuroleptics are also present when both medications are administered in rather low daily dosages (min. 2 mg/d; max. 8 mg/d).

Detailed Description

Considering that first episode schizophrenic patients compared to multiple episode patients respond to lower dosages of neuroleptics, the study aims to reach neuroleptic response under the lowest possible dosage of the study medication (haloperidol or risperidone). Therefore the initial dosage of the study medication is 2 mg/d. Depending on the patients' symptomatology, the daily dosage of the study medication can be increased by 2 mg in weekly intervals up to a maximum dosage of 8 mg/d. Patients with the diagnosis of schizophrenia (F20, according to ICD-10-criteria) are consecutively enrolled in the study. The patients are assessed at weekly intervals during the acute inpatient treatment phase of 8 weeks. Apart from the weekly psychopathological characterisation additionally neuropsychobiological data are assessed at the time of admission and at the end of the study. Major questions of the study are, whether patients, who have been treated with risperidone compared with those, who have been treated with haloperidol show a better treatment outcome regarding negative symptoms and exhibit fewer extra-pyramidal motor side effects. Furthermore it is hypothesised, that the treatment with Risperidone has better effects on cognitive disorders/dysfunctions and depressive symptoms and that the patients, who receive Risperidone are more compliant and have a higher quality of life.

Registry

clinicaltrials.gov

Start Date

November 2000

End Date

December 2004

Last Updated

20 years ago

Study Type

Interventional

Study Design

Parallel